From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|April 27, 2022
- April 2022
- Volume 88
- Issue 4
Pet Peeves: April 2022
Brought to you by The Sassy Pharmacist
Advertisement
Spelling Bee Champion
When people spell their name instead of saying John Smith.
Coupon Clippers
When people give you manufacturer coupons at pick up.
Time Crunch
When people ask if we can get the medication ready and they’ll bring the prescription when they come to pick up, “to save time.”
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
over 4 years ago
Case Studies: April 2022over 4 years ago
Generic Product News: April 2022over 4 years ago
OTC Cases: April 2022over 4 years ago
RX Product News: April 2022over 4 years ago
Bijuva From TherapeuticsMDover 4 years ago
Support Individuals Who Abuse Alcoholover 4 years ago
OTC Product News: April 2022over 4 years ago
Services to Improve Therapeutic Outcomes Improve Star Ratingsover 4 years ago
Worldwide Generics Market Will Exceed $507 Billion in 4 YearsAdvertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
4
Glucose Monitoring: Timing Makes Every Reading Count
5